Podcasts about Dan Barouch

There's a lot of anxiety this week as the public, politicians and even some scientists are moving on from restrictions and mask-wearing that defined the last two years. And yet, SARS-CoV-2 is very much still with us, a sub-variant called BA.2 is still posing a threat, and new variants are likely to emerge. And there's evidence that protection from our booster shots could wane. Immunologist Dan Barouch of Harvard and Beth Israel Deaconess Medical Center will talk about all these threats, address scientists' new appreciation for “natural immunity” and explain how he and other scientists will continue to fight the pandemic in months to come. “Follow the Science" is produced, written, and hosted by Faye Flam. Today's episode was edited by Seth Gliksman with music by Kyle Imperatore. If you'd like to hear more "Follow the Science," please like, follow, and subscribe!

That's a hard question, with a sudden change in CDC recommendations that everyone over 18 get one and not much explanation. Scientists have started to change their minds about boosters as they've seen more breakthrough cases. Another rationale was protection against the new variant – omicron - but it's not clear how well our vaccines will work against omicron if it becomes dominant. My guest is Dan Barouch, who is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and a researcher at Harvard Med School. A few years before the pandemic he designed a new kind of vaccine that became the J&J shot. He also led the team that adapted this vaccine to Covid-19 and did the pre-clinical studies that prepared it for human trials. “Follow the Science" is produced, written, and hosted by Faye Flam, with funding by the Society for Professional Journalists. Today's episode was edited by Seth Gliksman with music by Kyle Imperatore. If you'd like to hear more "Follow the Science," please like, follow, and subscribe!

Power & Politics for Friday, March 5th with Procurement Minister Anita Anand, Health Canada Chief Medical Adviser Dr. Supriya Sharma, Johnson & Johnson vaccine co-creator Dr. Dan Barouch, Parliamentary Secretary Anita Vandenbeld, Conservative Ethics Critic Michael Barrett, NDP Defence Critic Randall Garrison, and the Power Panel.

We speak about what this means with Dr. Dan Barouch, the director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. We also speak with WBUR's Carey Goldberg, one last time, about the latest vaccine and coronavirus news.

As we reflect on this one-year anniversary of the first coronavirus case in Massachusetts, we speak with Dr. Dan Barouch.

Dr. Dan Barouch is the director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, and is helping develop Johnson & Johnson’s vaccine candidate. CNN Chief Medical Correspondent Dr. Sanjay Gupta talks to him about how this vaccine is different, and how soon it could reach Americans.  To learn more about how CNN protects listener privacy, visit cnn.com/privacy

While the U.S. and European nations are still struggling to curb the spread of the virus, China appears to be recovering well. How did it do it? Dr. Eric Feigl-Ding explains the social solidarity and collective trust in health rules may bear fruit. A coronavirus-positive couple gets arrested after flying to Hawaii. Attorney Lou Shapiro says there is a legal foundation for criminally charging the duo.A new blood test might be able to predict the effectiveness of a COVID-19 vaccine. Dr. Dan Barouch describes the new research by Beth Israel Deaconess Medical Center.There's some optimism Congress may be able to reach an agreement on the second COVID-19 stimulus package. But Prof. David Fiorenza from the Villanova School of Business says, even if the deal is made today, the first round of checks won't reach Americans until January.  To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

While the U.S. and European nations are still struggling to curb the spread of the virus, China appears to be recovering well. How did it do it? Dr. Eric Feigl-Ding explains the social solidarity and collective trust in health rules may bear fruit.  A coronavirus-positive couple gets arrested after flying to Hawaii. Attorney Lou Shapiro says there is a legal foundation for criminally charging the duo. A new blood test might be able to predict the effectiveness of a COVID-19 vaccine. Dr. Dan Barouch describes the new research by Beth Israel Deaconess Medical Center. There's some optimism Congress may be able to reach an agreement on the second COVID-19 stimulus package. But Prof. David Fiorenza from the Villanova School of Business says, even if the deal is made today, the first round of checks won't reach Americans until January.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Influencers with Andy Serwer: Dr. Dan Barouch See acast.com/privacy for privacy and opt-out information.

Influencers with Andy Serwer: Dr. Dan Barouch See acast.com/privacy for privacy and opt-out information.

On Meet the Press, an exclusive joint interview with Dr. Peter Hotez, Director, Texas Children’s Hospital Center for Vaccine Development and Dr. Dan Barouch, Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center. Gov. Mike DeWine (R-Ohio) talks to Chuck Todd about the importance of masks, during an exclusive interview. National Security Adviser Robert O’Brien says China is risking sanctions by pushing for more control over Hong Kong. Andrea Mitchell, O. Kay Henderson and Jeh Johnson join the Meet the Press roundtable.

Why have scientists struggled to generate a protective HIV vaccine? Dan Barouch lays out the unique challenges and discusses the ongoing clinical trial with an adenovirus-based vaccine developed in his lab. Julie’s Biggest Takeaways HIV poses unique and unprecedented challenges for vaccine development including: Viral diversity: extremely wide range of viral diversity. No natural precedent: No human has cleared HIV based on their immune responses. Unknown correlates of protection: scientists are unsure what immune responses are important to induce. Barouch’s group uses a vaccine strategy comprised of computationally optimized mosaic HIV Env proteins, which represent pieces of the outermost glycoprotein, Env, that have been tied together in a way expected to generate protective immunity. Early data from animal and human trials suggests these mosaic antigens generate an immune response to a wider array of HIV types than previous vaccines. Clinical trials are ongoing to see if a strategy of mosaic antigen vaccination, followed by a boost with Env protein, is protective in people. Attenuated HIV hasn’t been used as a vaccine strategy because of fears it could revert to a disease-causing form; similar fears have prevented a whole-killed virus platform for vaccine development. A clinical trial testing safety in 3 locations around the world demonstrated that this vaccine strategy in people elicited immune responses shown to be protective in animals. An efficacy trial is ongoing in sub-Saharan Africa, with results expected in 2021. The trial is double blinded: neither the doctor nor the patient know who was administered the candidate vaccine or who was administered the placebo. HIV latent infection causes complications in vaccine development because HIV latency is seeded early, possibly in the first few days of infection. Once latency is established, the individual is infected for life. Any low level of HIV infection in vaccinated people could potentially seed this latent infection. Quickly-seeded latency means immune responses must react extremely quickly. Featured Quotes “The challenges in the development of a prophylactic HIV vaccine are among the toughest challenges in biomedical and scientific research.” “HIV poses unique challenges for vaccine development and truly unprecedented challenges that have never been posed before by vaccination. One such challenge is the viral diversity: HIV exists not as a single sequence, but as numerous different viral sequences — not only throughout the world, but also throughout regions, communities, and even within the same individual. So to create a vaccine against HIV, the immune responses have to be relevant for a vast diversity of viral sequences.” “At what efficacy level would an HIV vaccine be licenced by both the industry partners as well as the government regulators in a particular country, and at what level of efficacy would it actually have a major public health impact? It’s a moving target over time; it really depends on what the current state of the epidemic is at the time the vaccine is ready to be licensed.” “It’s critical to have high-quality research part of the clinical efficacy trials so that success or failure or something in between, that the HIV research field learns from it, and learns what worked well and what didn’t work well, and how to make better vaccines moving forward.” “I always encourage young scientists to pursue their dreams and to tackle hard problems. There’s a lot of easy problems to solve but some of the hardest problems are the most impactful in the end.” Links for This Episode MTM Listener Survey Barouch lab at the Center for Virology and Vaccine Research. MTM: Mark Connors. The Lancet: Evaluation of a Mosaic HIV-1 Vaccine in a Multicentre, Randomised, Double-Blide, Placebo-Controlled, Phase 1/2 a Clinical Trial (APPROACH) and in Rhesus Monkeys. The Lancet: A Step Forward for HIV Vaccines. Journal of Virology: Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. PLoS One: First-in-Human Randomized, Controlled Trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. HOM Tidbit: I am the Berlin Patient: A Personal Reflection. HOM Tidbit: Doctor who cured Berlin Patient of HIV: ‘We knew we were doing something very special’.

With more efficacy trials underway today than ever before in HIV prevention research, this episode of Px Pulse zooms in on two that have most recently launched: HPTN 084 and HVTN 705.  Veteran Malawian advocate Maureen Luba, Zimbabwe-based bioethicist Paul Ndebele, and leading scientist Dan Barouch each take up the subject of these trials and share their expertise on what they could mean for prevention nationally, regionally and globally.

Back in February the World Health Organisation declared the zika virus epidemic in Brazil to be a public health emergency of international concern. At the top of the list was the link between Zika infection and babies being born with microcephaly or an abnormally small head. Now scientists in the US have taken the first steps towards developing a much-needed vaccine, which they've so far tested successfully on mice. Dan Barouch from Harvard University spoke to Chris Smith... Like this podcast? Please help us by supporting the Naked Scientists

Back in February the World Health Organisation declared the zika virus epidemic in Brazil to be a public health emergency of international concern. At the top of the list was the link between Zika infection and babies being born with microcephaly or an abnormally small head. Now scientists in the US have taken the first steps towards developing a much-needed vaccine, which they've so far tested successfully on mice. Dan Barouch from Harvard University spoke to Chris Smith... Like this podcast? Please help us by supporting the Naked Scientists

Dr. Dan Barouch is the Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and Harvard Medical School and a Program Leader at the Reagan Institute of Massachusetts General Hospital, MIT, and Harvard University. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. D.H. Barouch. The Quest for an HIV-1 Vaccine - Moving Forward. N Engl J Med 2013;369:2073-6.